December 2006

Happy holidays to our members and supporters! We’re looking forward to working with you in 2007. Montana State University has made available for license a tolerizing agent for autoimmune, inflammatory and allergic reactions. The fusion protein is effective at extremely low doses to induce antigen-specific host tolerance in oral or nasal applications. A patent is pending and research is ongoing.

[button url=”” target=”_blank” size=”small” style=”limegreen” ]View Newsletter[/button]